Intellia Therapeutics posts Q3 2026 net loss of $127.5 million, $614.8 million in cash

what happened

According to TradingView, which drew on the company's SEC filing, Intellia Therapeutics brought in $7.2 million of collaboration revenue in the third quarter of 2026, down from $13.8 million a year earlier. The decline mainly reflected smaller payments from Regeneron.

The net loss reached $127.5 million, or $0.91 per basic and diluted share, compared with $101.3 million, or $0.92 per share, a year before. Research and development spending fell to $83.3 million, while general and administrative costs climbed to $46.1 million. Cash, equivalents and marketable securities stood at $614.8 million on September 30, 2026. The company also arranged a credit line of up to $400 million secured by its assets.

On the regulatory side, the FDA accepted the biologics license application for lonvoguran ziclumeran (lonvo-z) aimed at hereditary angioedema and assigned it Priority Review, with a PDUFA goal date of March 10, 2027. No advisory committee meeting is currently planned, and a U.S. launch is targeted for the first quarter of 2027 if approved.

why it matters

For investors, the key points are the cash runway and the regulatory timeline: the company says current resources should fund operations at least into 2028, while the lonvo-z decision is due in March 2027. The quarterly loss remains large relative to revenue, so the new credit line and the outcome of the drug review will be the main things to watch.

market impact

Intellia shares: wider loss and new credit line are the main factors for valuation

tags

instruments